Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials
-
Published:2024-08
Issue:8
Volume:42
Page:223-228
-
ISSN:1078-1439
-
Container-title:Urologic Oncology: Seminars and Original Investigations
-
language:en
-
Short-container-title:Urologic Oncology: Seminars and Original Investigations
Author:
Lotan YairORCID,
Agarwal Piyush,
Black Peter,
Dickstein Rian,
Kamat Ashish M.,
Lee Byron,
Narayan Vikram M.,
Porten Sima,
Psutka Sarah P.,
Smith Armine K.,
Svatek Robert S.,
Williams Stephen B.,
Woldu Solomon
Reference14 articles.
1. Advancing clinical trial design for non-muscle invasive bladder cancer;Chang;Bladder Cancer,2023
2. Bladder cancer, version 3.2023 bladder cancer NCCN guidelines;Flaig;J. Natl Compr Canc Netw,2023
3. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multi- centre, phase 2 study;Balar;Lancet Oncol,2021
4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial;Boorjian;Lancet Oncol,2021
5. Utility of blue light cystoscopy for post-bacillus Calmette-Guérin bladder cancer recurrence detection: implications for clinical trial recruitment and study comparisons;Chappidi;J Urol,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献